Literature DB >> 995159

Recovery from aplastic anemia after treatment with cyclophosphamide.

D T Baran, P F Griner, M R Klemperer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 995159     DOI: 10.1056/NEJM197612302952708

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

Review 1.  How I treat acquired aplastic anemia.

Authors:  Phillip Scheinberg; Neal S Young
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

Review 2.  Clinical management of aplastic anemia.

Authors:  Amy E Dezern; Robert A Brodsky
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

Review 3.  High-dose cyclophosphamide for autoimmunity and alloimmunity.

Authors:  Robert A Brodsky
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

4.  Complete remission of severe aplastic anaemia following treatment with anti-thymocyte globulin.

Authors:  M Griffin; L Coffey; S R McCann
Journal:  Ir J Med Sci       Date:  1983-08       Impact factor: 1.568

5.  Proceedings of the Annual Meeting of the European Foundation for Bone Marrow Transplantation, Sils Maria (Engadine), Switzerland, April 13-16, 1980.

Authors: 
Journal:  Blut       Date:  1980-09

Review 6.  Induction of auto-immune syndromes by penicillamine therapy in rheumatoid arthritis and other diseases.

Authors:  I A Jaffe
Journal:  Springer Semin Immunopathol       Date:  1981

7.  The value of prognostic indices in aplastic anaemia.

Authors:  D T Sleijfer; N H Mulder; H O Nieweg
Journal:  Blut       Date:  1981-02

8.  Neutropenia in three patients with rheumatic disorders. Suppression of granulopoiesis by control-sensitive thymus-dependent lymphocytes.

Authors:  G C Bagby; J D Gabourel
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

Review 9.  Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantages.

Authors:  Robert A Brodsky; Richard J Jones
Journal:  Autoimmunity       Date:  2008-12       Impact factor: 2.815

10.  Treatment of aplastic anemia with a monoclonal antibody directed against the interleukin-2 receptor.

Authors:  W Schwinger; C Urban; H Lackner; C Mache
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.